@blooddocdad: 1. Pancreatic cancer! A new drug, daraxonrasib, a RAS inhibitor, doubled overall survival from 6.7 to 13.2 months in metastatic pancreatic cancer 2. Multiple myeloma! A new class of drugs CELMoDs in relapsed multiple myeloma showed great responses. The future of myeloma 3. Myeloma again! Majestic 9 trial showed an immunotherapy, teclistamab, in second line improved survival over standard treatment 4. Breast cancer! The Serena 6 study, instead of waiting for scans to show progression, researchers used liquid biopsies to detect resistance mutations early and change treatment before the cancer visibly grew. This delayed the progression of disease 5. Brain metastases! The ROADs trial compared tile based radiation compared to stereotactic radiation therapy. Lower recurrence and better overall survival